Accelerators at Illumina, Healthbox pick first startups; Fitbit to track heart rate;

@FierceMedDev: Biocept, Rosetta Genomics want to beef up Dx and biomarker-detection power. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: Advisory board recommends that Arkansas Medicaid cut restrictions on $VRTX's cystic-fibrosis drug Kalydeco. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: Stem cell-derived beta cells deliver insulin in response to blood sugar levels. FierceDrugDelivery article | Follow @MichaelGFierce

> New accelerators at Illumina ($ILMN) and Healthbox Salt Lake City have disclosed their first companies. Illumina's first three companies include research tools and diagnostics company Xcell Biosciences. Utah's health tech-focused Healthbox chose 10 startups in its alumni class including connected sleep apnea device company Kosmo technologies; Liyen, which has a next-gen spacer for asthma inhalers; endotracheal intubation device company simplicityAirway; and peripheral arterial catheter player XableCath. Illumina release, Healthbox Salt Lake City release

> One of the new Fitbits that are soon to be released are rumored to include heart rate monitoring. Story

> Portal Instruments has raised an $11 million Series A from Sanofi ($SNY), PBJ Capital and an undisclosed U.S. medical device company to develop a computerized, needle-free drug delivery system for viscous biologics. Release

> Smith & Nephew ($SNN) has launched the Evos Mini Plating System for use in surgeries of the long bones of the arms and legs to address fracture reduction and short-term fixation prior to final repair. Release

Biotech News

@FierceBiotech: InterMune and Boehringer win tandem FDA nods for 'breakthrough' lung drugs. News | Follow @FierceBiotech

@JohnCFierce: Well that tax inversion business was a lot of fun--I wonder what the next big biopharma M&A trend will be. More | Follow @JohnCFierce

@DamianFierce: IPF drugs from $ITMN and Boehringer Ingelheim win FDA approvals at the same time. | Follow @DamianFierce

@EmilyMFierce: NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. More from FierceVaccines | Follow @EmilyMFierce

> AstraZeneca deepens its Cambridge ties with hopes for Alzheimer's and cancer. Story

> J&J adds an $817M cancer drug pact with ambitious Aduro. Article

> Moderna teams up with Karolinska to flesh out its mRNA promise. Item

Pharma News

@FiercePharma: Top-read in FiercePharmaMarketing Weds: World's best CEOs? Gilead, Allergan, Novo and Valeant make top 10. Article | Follow @FiercePharma

@EricPFierce: Remember when FDA asked heparin makers to test APIs for OCSC? This warning letter to a Chinese co. is why. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Have you seen FP's latest report? The top 10 most expensive drugs of 2013. Feature | Follow @CarlyHFierce

> AbbVie calls it quits on $55B Shire takeover. News

> Once again, Roche breast cancer franchise shines, sending Q3 drug sales up 4%. Article

Vaccines News

> Sanofi inks pact with Immune Design to boost herpes vax effort. Story

> Bexsero could be cost-effective for England, model says--but not at Novartis' price. Report

> Sanofi, Selecta join hands in diabetes vaccine push. Article

> NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. More

> Sanofi takes rotavirus vax into Phase III with eye on Indian market. Story

Pharma Manufacturing News

> FDA bans maker of suspect Chinese heparin. More

> Court orders Indian drugmaker to destroy $11M worth of unapproved drugs. Story

> FDA cites animal drug compounder for selling copies of Novartis' Capstar. Item

> Italy's Cosmos to build manufacturing plant in Ireland. News

> Abbott opens third nutrition plant this year. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.